Biologists Call For A Halt To ‘Mirror Life’ Research

A “mirror organism” would have proteins and DNA shaped in a way that’s the mirror image of how they naturally appear.

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:00Ira Flatow?

  Science Friday is supported by MathWorks, creator of MATLAB and Simulink software for technical computing and model-based design. MathWorks, accelerating the pace of discovery in engineering and science. Learn more at mathworks.com.

• 0:16Flora Lichtman?

  Science Friday is supported by Dell. Gifts mean more when they have the power to unwrap more of who you are. This Black Friday, give a gift that goes beyond the box: the Dell XPS 13 laptop. It's the thinnest, lightest XPS laptop yet, with a long battery life, beautiful design, and powerful performance with Intel Core processors. The XPS laptop unlocks more of what you love. Plus, at dell.com, you'll find perks like Dell Rewards, fast free shipping, and flexible financing, and big savings on monitors and accessories. Head to dell.com/deals. That's dell.com/deals.

• 1:06Speaker 02

  In a mirror organism, many important molecules would be in opposite-handedness of those in regular life. So why is that troubling to researchers?

• 1:15Speaker 03

  Why would you ever make a microorganism that's resistant to most of our antibiotics? That's a really bad idea.

• 1:20Speaker 02

  It's Wednesday, January 8th, and this is Science Friday.

• 1:27Speaker 02

  I'm SciFri producer Charles Bergquist. In so-called mirror life, proteins would be right-handed instead of left, while DNA would be left-handed instead of right. Recently, an international group of researchers argued that work toward creating that kind of organism should stop. Just don't do it. Synthetic biology researcher Drew Endy spoke with Ira about the concept of mirror life and some of the concerns in the research community. Here's Ira.

• 1:53Ira Flatow?

  Dr. Drew Endy is one of the authors of that warning. He's also an associate professor of bioengineering at Stanford University. Welcome to Science Friday.

• 2:02Speaker 03

  Glad to be here, Ira. Thanks for having me.

• 2:04Ira Flatow?

  Nice to have you. First of all, why might a researcher want to create some kind of mirror bacterium or other kind of life?

• 2:11Speaker 03

  It's like research in general. The motivations range from it's cool, doing something new is unbelievable. There's that element of it. And then it's also practical, like what's it good for? There's a lot of things that can be beneficial if you can make mirror molecules. They have different properties that might make a medicine last longer, or have different better impacts, fewer side effects. So it's everything from just pure basic science and the love of science to some fairly, you know, useful possibilities.

• 2:42Ira Flatow?

  Right. Well, you certainly have my interest now. So I want to delve a little bit deeper into this. For example, would would a mirror E. coli be just like a regular E. coli, but have right-handed proteins and left-handed DNA, for example?

• 2:57Speaker 03

  We think so, is one thing to admit, right? We have every reason to believe it would be a bacteria, but just be the mirror version of the bacteria. So imagine if you're looking at yourself in the bathroom mirror, and the mirror version of yourself came out of the mirror into the world, you'd still expect it to be you, it'd just be the mirror version of you. So we think that's what it would be like at the bacterial level, too, for what that's for.

• 3:23Ira Flatow?

  Do we have the technology for this today? Or are there still hurdles to actually overcome this?

• 3:29Speaker 03

  I would say significant hurdles. This is one of those things that is, we believe possible, but not imminent. One of the reasons why this article came together now is there's been tremendous progress in making mirror enzymes. So the enzymes that make nucleic acids, RNA and DNA. There's been incredible work by colleagues in China, researchers in China, to make mere RNA polymerase and mere DNA polymerase. And suddenly you can make mere nucleic acids, you know, the things that are at the core of life, the so-called central dogma. So you look at that and you go, wow, like this is really significant progress. On the other hand, you know, other things that biology absolutely needs,

• 4:13Speaker 03

  like the ribosome, the so-called molecular machine that makes proteins, nobody's made a mere ribosome. And that that's going to be a lot harder to pull off. So, you know, there's, there's debate within the research community in terms of how far away are we from somebody being able to do this? And some of my colleagues will say it's 10 years away or 30 years away, or it's never going to happen. I don't look at this so much like a scientific project. I look at this like a construction project. One of the things I've learned is, is when you're trying to explain how long it might take to do something, if it's a science project, I think it really has a lot of ambiguity. But if it's a construction project, the better way of thinking about how long it's going to take is not how much time it's going to take, but how much money it's going to take.

• 4:56Speaker 03

  And so I might imagine that it would, it would take somebody, you know, $500 million to make a serious attempt at building, say, a mere E. coli. Now, $500 million is a lot of money, to say the least. But when you look at the types of projects that get organized in research these days, you think about the artificial intelligence work. There's a lot of people who can organize that amount of money.

• 5:19Ira Flatow?

  Right.

• 5:20Speaker 03

  And so from my perspective, you know, that, that really helped me feel that it was important to talk about this now before anybody could get organized enough to, to make a serious overall attempt at it.

• 5:32Ira Flatow?

  Okay, let's, let's talk about this. You, you and your colleagues who, who wrote, shared these opinions with you, you're very concerned about this. What are your concerns?

• 5:43Speaker 03

  Yeah, it's, it's interesting. For me, before this conversation started within the research community, I wasn't waking up in the morning and going, oh, my gosh, mere life. What are we going to do about it? However, when some very good colleagues approached me to talk about it, my background in engineering is about building cells, building regular cells, not mere cells. You know, I bring that type of expertise to the puzzle. The initial concerns expressed are that if you made a mere E. coli, that such a bacteria would be able to get into our bloodstream, get into our bodies, and our immune system would have a very difficult time recognizing it, developing an immune response to it. And so suddenly, the type of infection you might be at risk of would be greater than normal.

• 6:25Speaker 03

  You know, eventually, it might figure it out, but at which point, your immune system might be on its heels. So that's more than a little bit concerning, and you could start there. Of course, we should be able to develop antibiotics, but they'd have to be new antibiotics. And so if you look at this, why would you ever make a microorganism that's resistant to most of our antibiotics? That's a really bad idea. So a lot of people start with that, and that in itself is sufficient. Actually, I should back up and say something pretty carefully. When people hear about the idea of, say, a mere E. coli, it'd be like, well, it would have to grow on mere food. You know, the inputs that power this E. coli, where are they going to come from? Because a mere bacteria would eat mere food, right?

• 7:10Speaker 03

  And that'd be a reasonable assumption to make. But not every molecule is a mere molecule. There are some things that don't have chirality, don't have handedness, things like glycerol. And so E. coli can grow on things that are not chiral. And so within your bloodstream, there's enough food, we believe, for a mere version of a microorganism to reproduce. The other thing that people often wonder about is where are the amino acids, the building blocks of the proteins going to come from and have the mere handedness? And these bacteria that we already have in nature are pretty well-equipped. They've got a good biochemical kit, and they actually can make all their amino acids if they need to. And so E. coli can already make all 20 amino acids.

• 7:53Speaker 03

  And so a mere E. coli could make all the mere ingredients it needs to reproduce. But in any case, the thing that really did it for me was when we started talking about nature and ecology. And so imagine if a bacteria, a mere bacteria, was made and it got out into the environment. It would come into competition with all the natural organisms and, you know.

• 8:18Speaker 03

  I don't think it would take over in and of itself, but it would probably establish a niche, be hanging out there. And so then the question is, so what? And then the problem becomes, and this might sound a little funny or strange, think about all the other creatures that are now going to encounter this thing. Like, my favorite example is chipmunks. I love chipmunks. And so if a mere bacterium could infect a person, it could probably infect a chipmunk too. And unlike a person, I'm not going to be able to go to clinic and get antibiotics, the new MIR antibiotics, the chipmunk's just going to get, be toast. And so having a mere microorganism that was promulgating through the environment and establishing itself as a, basically in different new niches in the environment, would seem

• 9:02Speaker 03

  to offer the possibility of a fairly grave hazard to many, if not most, other creatures out there in our various ecologies. And that, to me, feels closer to existential, something I don't want to touch with a 10-foot pole.

• 9:17Ira Flatow?

  Right. Do people working in this field see the threat that you do? You said that their existential threat is not quite your existential threat. But is there any form of ethics here about stopping this work like there was back in the 70s when genetic engineering started, to stop it and say, hey, let's think about what we're doing here?

• 9:41Speaker 03

  I think that's exactly what this article is about. You've got a significant coalition of scientists from many countries, some of whom had been doing work towards building MIR life, and we're all coming together and we're saying, don't do it, and let's talk about it.

• 9:57Ira Flatow?

  How would you talk about, how would you get together and talk about it?

• 10:00Speaker 03

  There's a couple of different things, right? So one thing we've done is created a resource where people can ask for money to get together and have a conversation about it. So there's a, you track down a website called MIR Biology Dialogues, and you want to have a meeting to talk about this, you know, seriously, you can get some support. So there's going to be a whole bunch of conversations throughout this year, including Institute Pasteur, to talk about it. Since you mentioned in passing the conversations in the 1970s, it's worth acknowledging that the big conversation happened in February of 1975 at Asilomar, California. So the 50th anniversary of that event is coming up next month.

• 10:43Ira Flatow?

  That was Paul Berg, I think, if I recall.

• 10:46Speaker 03

  Yeah, my late colleague Paul Berg and others, Maxine Singer, in Baltimore,

• 10:53Speaker 03

  they organized that meeting in February 1975. We are having an event at Asilomar at the end of February to talk about things arising in biotechnology today and how to best mind them. One of the five topics we'll discuss is building cells and near cells, the possibility of near cells specifically. So that's another example of a conversation coming up soon.

• 11:16Ira Flatow?

  Right. That's interesting to know because I remember that conference. Let me just backtrack a bit and understand exactly what you're saying. Are you saying do not every do it at all? Or can you see a place in which it can be done safely?

• 11:31Speaker 03

  Right now, we're saying, don't do it. And, you know, let's stop working towards this goal and not proceed further. You know, if people want to put forward a good case for why we're wrong, we'd love to hear that. But right now, our position is let's not do this. You know, I want to give a lot of credit to the colleagues working together to do this. You know, again, you know, some of the signatories on this and authors of the piece are folks who had, you know, until before we had this conversation, this is what they're doing. And they've decided that, you know, very courageously, it's like, actually, you know, I've thought about this, and this is a bad idea, and we shouldn't do it. You know, again, somebody's not going to do this tomorrow. It would take at least a thousand

• 12:14Speaker 03

  days of a thousand people working on it. That's as fast as you could do it, I think. Right? And so it's a type of decision making process. It's more like deciding where you want to sail when you're leaving the harbor, but before you leave the harbor, or as you're leaving the harbor, as opposed to, hey, I better steer the ship when we're about to crash on the reef.

• 12:32Ira Flatow?

  Right.

• 12:32Speaker 03

  You know, what was it? It was in 2023, when you had a whole bunch of folks in artificial intelligence, you know, frantically signing letters about the dangers of AI. But like meanwhile, you've got huge organizations fired up, running as fast as they can to make artificial general intelligence that, you know, that that's what it looks like when you're trying to steer the ship and you're very close to crashing on the shores, right? Whereas whereas like here, I think we're actually some, some people would say you're too early. You know, this isn't imminent, but actually that's when you want to make good decisions, when it is too early.

• 13:06Speaker 02

  After the break, a look at some more hopeful applications of synthetic biology. Stay with us.

• 13:17Speaker 04

  WNYC Studios is supported by Wise. Wise, the smart way to manage the currencies you need around the world. With a Wise account, you can send, spend and receive in up to 40 currencies with only a few simple taps. Be smart, get wise. Download the Wise app today. Terms and conditions apply. Science Friday is supported by PBS, presenting Going Wild. If you love learning about the natural world and meeting the scientists who help us understand it, be sure to check out the new season of Going Wild with Dr. Ray Wynn Grant. It's the chart topping and Webby award winning podcast from the folks at Nature on PBS, now with a video companion series. In this season of Going Wild, host acclaimed wildlife ecologist Dr. Ray Wynn Grant heads out into the field to explore the animals,

• 14:01Speaker 04

  people and stories that make nature worth saving. Stops include a hibernating black bear den in Arkansas and an underwater shipwreck site off the Florida coast. If you're looking for a place to start, check out the season's debut episode where Ray joins beloved biologist and influencer Jordan King in the Florida Everglades to learn about his unlikely journey into science and how to study a wetland when it's not very, well, wet. So don't miss out. Follow Going Wild with Dr. Ray Wynn Grant on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. WNYC Studios is supported by Odoo. When you buy business software from lots of vendors, the costs add up and it gets complicated and confusing. Odoo solves this. It's a single company that sells a suite of enterprise

• 14:45Speaker 04

  apps that handles everything from accounting to inventory to sales. Odoo is all connected on a single platform in a simple and affordable way. You can save money without missing out on the features you need. Check out Odoo at O D O O dot com. That's O D O O dot com. WNYC is supported by Bear. Every day in America, science delivers, not just in the headlines, but in the moments that matter most. Science is a journey, one of curiosity, persistence, and progress. It's about asking questions, testing, learning, and improving again and again. Science delivers harvests that feed families, tools that help farmers grow more with less, and new ways to protect land for generations to come.

• 15:30Speaker 04

  Let's keep asking, keep testing, keep discovering, so science can keep delivering. Learn more at sciencedelivers.com.

• 15:43Ira Flatow?

  You know, this all sounds somewhat threatening for just a few days into the new year. But let's talk about some positive things. What are you excited about in your field of synthetic biology? What should we be looking forward to?

• 15:58Speaker 03

  Well, I put my engineer hat on. The way I think about it is the physics of flourishing are really terrific. Biology as a domain, living systems, they and we operate at this intersection of energy and materials. You think about photosynthesis, all the plants on Earth. They're harvesting about 100 terawatts of energy. A civilization's running on about 20 terawatts of energy. You know, so just 100 is five times more than 20. So when I say the physics of flourishing are outstanding, are really good, what that suggests, you know, just the back of the envelope math is if we could partner with biology correctly, we could get to a near future where, within a generation,

• 16:40Speaker 03

  humanity would be able to equip ourselves with the capacities to make the stuff that we need without being in conflict with the rest of life on Earth. Right? So it's fairly easy for me to imagine things working out pretty well on this planet. And for that to be true within our children's generation, if we just went all out and made it real. So then to come back to your question, Ira, you know, like, what's going on with synthetic biology? If you've never heard about synthetic biology before, It starts with the word synthesis and I'm in love with the word synthesis. It's you go back into the history of that word. It means composition or putting together. Think of a musical synthesizer, you know, composing a piece of music or performing a dance.

• 17:24Speaker 03

  And so when you put the word synthesis in front of biology, you know, we're learning how to compose biology. This field in its modern form is about 20 years old now. And just looking at the arc of basic progress in the in the field, we're starting to get better and better and better at composing biology. People are building very complicated pathways inside cells to make medicines in new ways. This last year in 2024, I don't know about you, but I had two bioengineered creatures in my house. One was a bioluminescent petunia that emits light. I gave it to our, our boys that they were nightlights. And then these so-called blueberry tomatoes with some Snapdragon genes in them that make antioxidants like in blueberries.

• 18:10Speaker 03

  I don't grow a lot of tomatoes, but these are the first tomatoes I, I, I grew and they're pretty good. But, but it's, it's interesting, right? It's like this first time in my life, I'm a consumer of a, of a, we have consumer electronics. Now we have consumer biologics. Uh, and so that was shocking in a good way to me last year. I've got a colleague, Mike Fishbach at Stanford, who's done incredible work with his team on reprogramming the bacteria that live on our skin. There's a microbe called Staph epidermidis. And they can have that organism present an antigen and tickle your immune system. So it develops an immune response. This has been done in mice, not people. One of the early demonstrations was to develop an immune response against melanoma.

• 18:54Speaker 03

  So imagine having a skin cream that vaccinates you against skin cancer. There are a lot of reasons in my world to be excited about what biology could offer. And when you zoom all the way out to the planetary scale, you know, it feels like we can develop biotechnology in safe and responsible ways. And, and basically give it to folks so that they can solve local problems. If, if I link it back to the topic of, of building cells, the thing that's still true about bioengineering today. It's like, um, before we had the light bulb and, and, you know, Edison and folks were working on, how do you get a light bulb to work? And they had, how many, how many light bulbs did they have to, prototypes they have to test? And it was like tinker and test, tinker and test.

• 19:36Speaker 03

  Bioengineering is like that still because biology is still very mysterious at its core. There's no, there's no cell on earth that we totally understand yet. And so what that means is we take our best and brightest ideas. And once we implement them in a, in a, in a DNA molecule, we have to test that molecule to see if it's actually going to work. And we don't know ahead of time. It's not like building a building or even building a bridge or airplane where our models are good enough, we can test it on the computer before we build it. You really have to test biology in reality to show that your designs work. The most exciting thing to me, I think we're on the precipice of understanding how to build cells, natural cells, not mere cells.

• 20:17Speaker 03

  And that will become a foundational platform, a big breakthrough that makes routine the building of biological systems at the cellular scale. I, I think of it like there were computers before operating systems and then computers after operating systems. And I see that bioengineering is about to get its first operating system at the cellular scale. So that, that's what I'm most excited about. If you want me to nerd out, you know, that's, that's where I am.

• 20:43Ira Flatow?

  Well, we'll have you come back and talk about this because this is fascinating. Dr. Endy, happy new year and thank you for enlightening us about this fascinating world.

• 20:53Speaker 03

  Happy 2025, Ira. Looking forward to making the world pretty good.

• 21:00Speaker 02

  And that's it for today. Tomorrow, we'll whisk you away through the magic of radio to the Pacific Northwest for a look at the world of Lykan's. Lots of folks helped make the show happen, including

• 21:11Speaker 05

  Jason Rosenberg. George Harper.

• 21:14Speaker 06

  Kathleen Davis. Shashana Buckstom.

• 21:16Speaker 02

  And many more. I'm sci fi producer Charles Burquist. Thanks for listening. We'll see you soon.